Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

NCT00759239 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Open-angle Glaucoma
Ocular Hypertension

Interventions

DRUG: Travoprost 0.004% / Timolol maleate 0.5%
DRUG: Travoprost 0.004% / Timolol maleate 0.5%

Sponsor

Alcon Research